ClinicalTrials.gg
Not yet recruitingNCT07815158Updated Sep 11, 2026

Multi-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults

An interventional study of Multi-Component Nutritional Formula and matched placebo in Sarcopenia and Intrinsic Capacity, sponsored by National Yang Ming Chiao Tung University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Sarcopenia with a site in Taiwan — 30 open to participants now, 31 under way, none of them phase 3. Sarcopenia · Taiwan.

Planned enrollment
37th of 67
70 · median 80
Started
2026
with 9 others
No phase
63 of 96
22 open now
Primary completion
2026-12
later than 18 of 30 live
Registered
95th of 96
by date

Among the 96 studies in Sarcopenia with a site in Taiwan, this one is the 37th largest by planned enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2026, is one of 63 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 95th registered.

Sarcopenia

1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

30 of the 96 studies in Sarcopenia with a site in Taiwan are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Sarcopenia with a site in Taiwan, or all of them as a file.
02

Study summary

To evaluate the effects of a 12-week multi-component nutritional formula on World Health Organization (WHO) Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Besides, the investigators use standardized ICOPE Step 2 assessments, functional capacity scales, and metabolic biomarkers (including GDF-15, HOMA-IR, TyG index, LAP, and FIB-4) as outcome measures to validate whether the multi-component nutritional supplement could improve intrinsic capacity and health in older adults.

Read the detailed description

With aging, physiological functions and intrinsic capacity across multiple domains decline, leading to increased risks of sarcopenia, frailty, and metabolic dysfunction. The World Health Organization (WHO) introduced the Integrated Care for Older People (ICOPE) framework - covering locomotion, vitality, cognition, psychology, vision, and hearing - to promote healthy aging. This double-blind randomized controlled trial evaluates whether a 12-week intervention using an 18-component multi-component nutritional formula can improve ICOPE intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Through this trial, investigators aim to establish clinical evidence for nutritional strategies in managing age-related functional and metabolic declines.

03

Conditions studied

  • Sarcopenia
  • Intrinsic Capacity

Keywords

  • Sarcopenia
  • frailty
  • intrinsic capacity
  • Physical Function
  • Metabolic Biomarkers
  • Multi-Component Nutritional Supplement
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 65 years and older.
  2. Intact consciousness and cognitive ability to understand and cooperate with the study protocol.
  3. Capable of oral ingestion and self-administration of the study formula/placebo.
  4. Meets at least one of the following priority recruitment criteria:

    1. Screened positive for decline in at least one WHO ICOPE intrinsic capacity domain (locomotion, vitality, cognition, psychology, vision, or hearing).
    2. Sarcopenia risk based on AWGS 2019 criteria: low handgrip strength (\<28 kg for men; \<18 kg for women), slow 6-meter gait speed (\<1.0 m/s), or Short Physical Performance Battery (SPPB) score ≤ 9.
  5. Ability to attend scheduled hospital outpatient visits at baseline (Week 0) and Week 12.
  6. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Severe hepatic impairment (GPT/ > 3 times the , or a confirmed diagnosis of liver cirrhosis).
  2. Severe renal impairment (serum creatinine ≥ 2.0 mg/dL, \< 30 mL/min/1.73m², or a confirmed history of renal failure, chronic kidney disease, uremia, or dialysis).
  3. Confirmed clinical diagnosis of dementia.
  4. Active malignant neoplasms currently undergoing active oncological therapy (chemotherapy, radiotherapy, or targeted therapy).
  5. Current use of oral anticoagulant medication (Warfarin) due to potential interactions with fish oil and vitamin K2.
  6. Known allergy or to any ingredient of the study product (dairy, soy, or fish sources).
  7. High-dose supplementation with whey protein, fish oil, or botanical extracts within the past 3 months.
  8. Presence of an active middle-ear implant or cochlear implant (to eliminate confounding factors during hearing assessments).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Experimental: Multi-Component Nutritional Formula Group

    Participants in this group receive the active 18-component multi-component nutritional formula daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity.

    Dietary Supplement: Multi-Component Nutritional Formula

  • Placebo comparator
    Placebo Comparator: Matched Placebo Group

    Participants in this group receive an appearance-, flavor-, and taste-matched placebo powder daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity.

    Dietary Supplement: matched placebo

Interventions

  • Dietary supplementMulti-Component Nutritional Formula

    Daily oral consumption of the multi-component nutritional powder dissolved in warm water for 12 weeks. The formula contains muscle-anabolic proteins (whey protein, yeast protein, leucine), bone-supportive nutrients (MBP, coral calcium, vitamins D3/K2), and bioactive compounds (mulberry leaf extract, astragalus, grape seed extract, phosphatidylserine, fish oil, and lutein).

  • Dietary supplementmatched placebo

    Daily oral consumption of the matched placebo powder dissolved in warm water for 12 weeks. The placebo is calorie-matched (within 10% caloric difference) but contains no active proteins, free amino acids, calcium/vitamin D3/K2 supplements, fish oil, or botanical extracts.

06

What researchers measure

Primary outcomes

  1. Change in Locomotion Measured by Short Physical Performance Battery (SPPB)

    Assessed by the Short Physical Performance Battery (SPPB), covering balance, chair stand, and gait speed. Scores range from 0 to 12, where higher scores indicate better lower-extremity physical function.

    Time frame: Baseline, Week 12

  2. Change in 6-Meter Gait Speed

    Measured by the 6-meter gait speed test in meters per second (m/s). Higher speed indicates better physical mobility

    Time frame: Baseline, Week 12

  3. Change in Handgrip Strength

    Measured in kilograms (kg) using a handheld dynamometer on the dominant hand (maximum of two trials). Higher values indicate greater muscle strength.

    Time frame: Baseline, Week 12

  4. Change in Nutritional Status by MNA-SF

    Assessed by the Mini Nutritional Assessment-Short Form (MNA-SF). Scores range from 0 to 14, where scores ≤11 indicate malnutrition risk and higher scores represent better nutritional status

    Time frame: Baseline, Week 12

  5. Change in Body Weight

    Measured in kilograms (kg) under fasting conditions.

    Time frame: Baseline, Week 12

  6. Change in Calf Circumference

    Measured in centimeters (cm) at the widest part of the calf. Higher values indicate greater muscle mass reserve.

    Time frame: Baseline, Week 12

  7. Change in Cognitive Function by MoCA

    Assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores reflecting better global cognitive performance.

    Time frame: Baseline, Week 12

  8. Change in Depressive Symptoms by GDS-5

    Assessed by the 5-item Geriatric Depression Scale (GDS-5). Scores range from 0 to 5, where higher scores indicate greater depressive symptoms (scores ≥2 suggest depression risk).

    Time frame: Baseline, Week 12

  9. Change in Visual Impairment Status

    Evaluated based on WHO ICOPE Step 2 vision assessment criteria (classified as visual impairment: Yes or No).

    Time frame: Baseline, Week 12

  10. Change in Hearing Impairment Status

    Evaluated using the whisper voice test based on WHO ICOPE Step 2 criteria (classified as hearing impairment: Yes or No).

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change in Basic Activities of Daily Living by Barthel Index

    Scores range from 0 to 100, where higher scores indicate greater independence in physical functioning and personal care.

    Time frame: Baseline, Week 12

  2. Change in Instrumental Activities of Daily Living by Lawton IADL Scale

    Assessed using the Lawton Instrumental Activities of Daily Living (IADL) Scale, with scores ranging from 0 to 8, where higher scores indicate better ability to perform instrumental activities of daily living.

    Time frame: Baseline, Week 12

  3. Change in Frailty Status by Fried CHS Phenotype

    Evaluated using the Fried Cardiovascular Health Study (CHS) criteria (0 to 5 criteria), categorizing participants as robust (0), pre-frail (1-2), or frail (3-5).

    Time frame: Baseline, Week 12

  4. Change in Clinical Frailty Scale (CFS)

    Measured using the Clinical Frailty Scale (CFS), with scores ranging from 1 to 9, where higher scores indicate greater frailty and a worse outcome.

    Time frame: Baseline, Week 12

  5. Change in Quality of Life by SF-36 Health Survey

    Assessed by the Short Form 36 (SF-36) questionnaire, evaluating physical and mental health component summary scores (scores 0-100, higher scores reflect better quality of life).

    Time frame: Baseline, Week 12

  6. Change in Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis (BIA)

    Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Skeletal Muscle Mass Index (SMI) is expressed in kg/m². Higher SMI values indicate greater skeletal muscle mass relative to height and a better outcome.

    Time frame: Baseline, Week 12

  7. Change in Visceral Fat Area by Bioelectrical Impedance Analysis

    Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Visceral Fat Area (VFA) is expressed in cm². Higher VFA values indicate greater visceral adiposity and a worse outcome.

    Time frame: Baseline, Week 12

  8. Change in Body Fat Percentage by Bioelectrical Impedance Analysis

    Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Body Fat Percentage is expressed as a percentage (%). Higher body fat percentage indicates a greater proportion of body fat and a worse outcome.

    Time frame: Baseline, Week 12

  9. Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    calculated by Homeostatic Model Assessment for Insulin Resistance, HOMA-IR

    Time frame: Baseline, Week 12

  10. Change in Triglyceride-Glucose (TyG) Index

    calculated by Triglyceride-Glucose Index, TyG index. Higher values indicate greater metabolic and insulin resistance risk.

    Time frame: Baseline, Week 12

  11. Change in Lipid Accumulation Product (LAP)

    calculated by Lipid Accumulation Product, LAP. Reflects visceral adiposity.

    Time frame: Baseline, Week 12

  12. Change in Serum Growth Differentiation Factor-15 (GDF-15)

    measured by serum Growth Differentiation Factor-15, GDF-15, as a circulating biomarker of biological aging and mitochondrial stress.

    Time frame: Baseline, Week 12

  13. Change in Fibrosis-4 (FIB-4) Index

    calculated by Fibrosis-4 Index, FIB-4. Used to estimate hepatic steatosis-associated fibrosis risk.

    Time frame: Baseline, Week 12

  14. Change in Glycated Hemoglobin (HbA1c)

    measured by Glycated Hemoglobin, HbA1c

    Time frame: Baseline, Week 12

  15. Change in High-Sensitivity C-Reactive Protein (hs-CRP)

    Measured in mg/L as a circulating marker of systemic low-grade inflammation.

    Time frame: Baseline, Week 12

  16. Change in Serum 25-Hydroxyvitamin D [25(OH)D]

    Measured in ng/mL to reflect nutritional vitamin D status

    Time frame: Baseline, Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 3 months later.

Of 494 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 3 months is below that.

Counting every sponsor, half of 505 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Sep 11, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07815158
Collaborators
Kaohsiung Veterans General Hospital., Taiwan Association of Integrated Care
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 11, 2026

Study contacts

Chih-Kuang Liang
Contact
Ck.vghks@gmail.com
07-3422121 ext. 72091

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion